When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EPZM - FDA accepts Epizyme's application for tazemetostat for follicular lymphoma
Epizyme Inc.
Under Priority Review status, the FDA has accepted Epizyme's (NASDAQ:EPZM) marketing application seeking approval of Tazverik (tazemetostat) for the treatment of patients with relapsed/refractory follicular lymphoma who have received at least two prior lines of systemic therapy.
More news on: Epizyme, Inc., Healthcare stocks news,